“We truly see ourselves as an operating system for payers,” says David Pierre, CEO of Machinify. Pierre joins Bloomberg Intelligence analyst Jonathan Palmer to unpack how Machinify is using AI to reimagine payment integrity, turning a manual process into a proactive, tech-enabled platform. They discuss Machinify’s formation from four legacy and technology companies, its AI-first claims strategy and how the team is driving real-time adjudication and measurable cost savings. Pierre also shares what he’s learned from Cerner and Signify, and where Machinify is heading next.

&ldquo;We truly see ourselves as an operating system for payers,&rdquo; says David Pierre, CEO of Machinify. Pierre joins Bloomberg Intelligence analyst Jonathan Palmer to unpack how Machinify is using AI to reimagine payment integrity, turning a manual process into a proactive, tech-enabled platform. They discuss Machinify&rsquo;s formation from four legacy and technology companies, its AI-first claims strategy and how the team is driving real-time adjudication and measurable cost savings. Pierre also shares what he&rsquo;s learned from Cerner and Signify, and where Machinify is heading next.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care by Bloomberg Intelligence

How Machinify’s AI Platform Is Rewriting the Rules of Payer Ops

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/6128583b-f714-4eb5-a419-b31400e350a2/transcript

“Being privately held and being a pure play spine company has given us the focus, the resourcing and the investment we need to, to really take this thing and make it hum,” Highridge’s CEO Rebecca Whitney says about the 7th largest spine company. In this Vanguards of Health Care episode, Whitney sits down with BI analyst Matt Henriksson for an in-depth interview about the path to a private company from a subsidiary under a major, publicly traded ortho company. As an independent company, she explains how it can be nimble in M&A, including the acquisition of key expandable spinal implants from Accelus and the recent PathKeeper agreement, both of which augment Highridge’s portfolio that houses its Mobi-C cervical disc replacement system and Tether motion preservation system. She also explains the importance of saying yes to new roles to build your career trajectory.

&ldquo;Being privately held and being a pure play spine company has given us the focus, the resourcing and the investment we need to, to really take this thing and make it hum,&rdquo; Highridge&rsquo;s CEO Rebecca Whitney says about the 7th largest spine company. In this Vanguards of Health Care episode, Whitney sits down with BI analyst Matt Henriksson for an in-depth interview about the path to a private company from a subsidiary under a major, publicly traded ortho company. As an independent company, she explains how it can be nimble in M&amp;A, including the acquisition of key expandable spinal implants from Accelus and the recent PathKeeper agreement, both of which augment Highridge&rsquo;s portfolio that houses its Mobi-C cervical disc replacement system and Tether motion preservation system. She also explains the importance of saying yes to new roles to build your career trajectory.

Highridge Goes Private to Expand Differentiated Offering in Spine

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/28cb618b-c07f-41c2-891c-b3fc013f4647/transcript

“We’re going to continue to drive innovation across the entire product portfolio, which also includes how we manufacture sensors,” Dexcom CEO Jake Leach tells Bloomberg Intelligence, outlining the company’s strategy to expand the use of continuous glucose monitors to more diabetic patients and beyond. In this Vanguards of Health Care podcast episode, Leach joins BI analyst Matt Henriksson for an in-depth discussion on Dexcom’s transition to the G7 15 Day sensor, aimed to reduce the frequency of changing sensors, as well as clinical data efforts to expand reimbursement to diabetic patients not on insulin and updates on the next-generation G8. He also reflects on his 22-year journey at Dexcom, rising from an engineer on a 30-person team to CEO of an 11,000-employee company.

&ldquo;We&rsquo;re going to continue to drive innovation across the entire product portfolio, which also includes how we manufacture sensors,&rdquo; Dexcom CEO Jake Leach tells Bloomberg Intelligence, outlining the company&rsquo;s strategy to expand the use of continuous glucose monitors to more diabetic patients and beyond. In this Vanguards of Health Care podcast episode, Leach joins BI analyst Matt Henriksson for an in-depth discussion on Dexcom&rsquo;s transition to the G7 15 Day sensor, aimed to reduce the frequency of changing sensors, as well as clinical data efforts to expand reimbursement to diabetic patients not on insulin and updates on the next-generation G8. He also reflects on his 22-year journey at Dexcom, rising from an engineer on a 30-person team to CEO of an 11,000-employee company.

Dexcom Aims to Expand CGM Benefits to All Diabetic Patients and Beyond

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/891c992b-786d-4127-aa5e-b3f601084d6c/transcript

“We’re empowering health-care providers with unprecedented clinical depth in a compact portable form factor,” AliveCor CEO Priya Abani says about the development of its AI-enabled electrocardiogram (ECG) sensors, which provide medical-grade heart data anytime and anywhere. In this Vanguards of Health Care episode, Abani sits down with BI analyst Matt Henriksson for an in-depth discussion about the expansion of AliveCor’s Kardia 12L device, which gives physicians a smaller, more portable ECG option. The company has widened the device’s indications to 39 cardiac conditions, established a new Category III reimbursement code and continues to train its algorithm using 1 million ECGs. Abani also talks about how her time at Amazon.com influenced her perspective on the interaction of technology and the human experience.

&ldquo;We&rsquo;re empowering health-care providers with unprecedented clinical depth in a compact portable form factor,&rdquo; AliveCor CEO Priya Abani says about the development of its AI-enabled electrocardiogram (ECG) sensors, which provide medical-grade heart data anytime and anywhere. In this Vanguards of Health Care episode, Abani sits down with BI analyst Matt Henriksson for an in-depth discussion about the expansion of AliveCor&rsquo;s Kardia 12L device, which gives physicians a smaller, more portable ECG option. The company has widened the device&rsquo;s indications to 39 cardiac conditions, established a new Category III reimbursement code and continues to train its algorithm using 1 million ECGs. Abani also talks about how her time at Amazon.com influenced her perspective on the interaction of technology and the human experience.

AliveCor’s Priya Abani Uses Amazon Experience to Democratize ECG Tech

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/91a12a5f-8a31-43a0-8103-b3ef00e43ab8/transcript

How Machinify’s AI Platform Is Rewriting the Rules of Payer Ops

In 1 playlist(s)

Vanguards of Health Care by Bloomberg Intelligence

Social links

Follow podcast

Recent clips